Navigation Links
Terumo Cardiovascular Systems Responds to Allegations of Patent Infringement

ANN ARBOR, Mich., April 4, 2008 /PRNewswire/ -- Terumo Cardiovascular Systems (Terumo CVS) announced yesterday that it is responding to a patent infringement complaint by Maquet Cardiovascular LLC. The complaint alleges that Terumo CVS and its parent company, Terumo Corporation, had infringed on two patents related to the sale of the Terumo(R) VirtuoSaph(TM) Endoscopic Vein Harvesting System.

(Logo: )

Terumo CVS states that its policy and its practice are not to infringe on the valid intellectual property rights of any company. The VirtuoSaph system is protected by multiple Terumo patents.

"Frankly, we're surprised at this lawsuit as these patents are several years old and our product has been on the market for more than three years with great success," says Mark DiClemente, Vice President, Sales, Terumo Cardiovascular Systems. "Our competitor has only recently entered the vessel harvesting market through an acquisition."

Terumo CVS has sold the VirtuoSaph system in the United States since January 2005. The product is also distributed in Japan and Asia by Terumo Corporation and in Europe by Terumo's European subsidiary.

The VirtuoSaph system is used during coronary artery bypass grafting (CABG), the most common cardiac surgery procedure. During the procedure, the surgeon removes a healthy artery or vein from elsewhere in the body, most often the saphenous vein in the leg, and uses it to route blood around a blockage in a coronary artery. The VirtuoSaph system allows the surgical team to remove the saphenous vein using very small incisions. Endoscopic procedures have been shown to minimize scarring, morbidity and infection associated with traditional longitudinal incisions.

Terumo Cardiovascular Systems Corporation manufactures and markets medical devices for the global cardiac surgery and interventional markets. The company is headquartered in Ann Arbor, Michigan with manufacturing operations in Ann Arbor; Elkton, Maryland; Ashland, Massachusetts; and Tustin, California. It is one of several subsidiaries of Terumo Corporation of Japan focused exclusively on the cardiac and vascular markets, including Terumo Heart Inc., developer of a ventricular assist device. For more information, visit

Terumo Corporation is a premier global medical device company with annual sales in excess of 270,000 (million) yen for the year ending March 31, 2007. Founded in 1921, the company develops, manufactures and distributes world- class medical devices for use in cardiothoracic surgery, interventional procedures, transfusion medicine, and needle and syringe products.

SOURCE Terumo Cardiovascular Systems
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
2. Terumo Launches the New AZUR(TM) Peripheral HydroCoil(R) Embolization System with Expanding Hydrogel Technology
3. MAQUET Cardiovascular Announces Patent Infringement Complaints Against Terumo
4. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
5. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
6. Pot bellies linked to early signs of cardiovascular disease
7. Air pollution linked to cardiovascular risk indices in healthy young adults
8. Environmental stress probed in cardiovascular disease, diabetes
9. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
10. American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC)
11. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: